Tianjin Medical University Cancer Institute and Hospital
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
1. Must be competent and able to sign and date an Institutional Review Board (IRB) or Ethics Committee (EC)-approved ICF prior to any study-specific procedure or trial.
2. Female patients aged ≥18 years with advanced breast cancer who are adults.
3. Pathologically confirmed breast cancer that meets the following criteria:
1. unresectable or metastatic, with evidence of recurrent or metastatic disease.
2. HER2 overexpression, or HER2 hyperexpression as determined by the central laboratory in accordance with the American Society of Clinical Oncology-Society of American Pathologists guidelines.
4. Patients must have measurable lesions according to RECIST 1.1 criteria.
5. Unmenopausal, menopausal, and perimenopausal female patients were allowed to be enrolled.
6. Prior antitumor therapy against recurrent metastatic disease is allowed.
You may not be if
1. Early stage breast cancer
2. Patients who do not meet the criteria for HER2 overexpression and HER2 underexpression.
3. Female patients during pregnancy or lactation.
4. Patients deemed unsuitable for enrollment by the investigator.
Clareo Health | A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer
